X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs JUBILANT LIFE SCIENCES - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD JUBILANT LIFE SCIENCES ALEMBIC LTD/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 61.1 17.8 343.0% View Chart
P/BV x 2.6 4.7 54.4% View Chart
Dividend Yield % 0.4 0.4 103.0%  

Financials

 ALEMBIC LTD   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
JUBILANT LIFE SCIENCES
Mar-14
ALEMBIC LTD/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs72187 38.5%   
Low Rs3465 52.1%   
Sales per share (Unadj.) Rs4.7364.3 1.3%  
Earnings per share (Unadj.) Rs6.16.8 89.2%  
Cash flow per share (Unadj.) Rs6.224.5 25.5%  
Dividends per share (Unadj.) Rs0.203.00 6.7%  
Dividend yield (eoy) %0.42.4 15.9%  
Book value per share (Unadj.) Rs40.7164.9 24.7%  
Shares outstanding (eoy) m267.03159.28 167.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.30.3 3,258.6%   
Avg P/E ratio x8.718.4 47.2%  
P/CF ratio (eoy) x8.55.1 164.9%  
Price / Book Value ratio x1.30.8 170.5%  
Dividend payout %3.343.8 7.5%   
Avg Mkt Cap Rs m14,13920,061 70.5%   
No. of employees `000NA6.2 0.0%   
Total wages/salary Rs m20711,052 1.9%   
Avg. sales/employee Rs ThNM9,383.0-  
Avg. wages/employee Rs ThNM1,786.9-  
Avg. net profit/employee Rs ThNM176.3-  
INCOME DATA
Net Sales Rs m1,25558,034 2.2%  
Other income Rs m370191 194.2%   
Total revenues Rs m1,62558,224 2.8%   
Gross profit Rs m1115,786 1.9%  
Depreciation Rs m382,812 1.3%   
Interest Rs m23,237 0.1%   
Profit before tax Rs m442-72 -612.8%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m24696 3.4%   
Profit after tax Rs m1,6301,090 149.5%  
Gross profit margin %8.910.0 88.8%  
Effective tax rate %5.4-965.9 -0.6%   
Net profit margin %129.81.9 6,910.8%  
BALANCE SHEET DATA
Current assets Rs m1,86729,280 6.4%   
Current liabilities Rs m59138,912 1.5%   
Net working cap to sales %101.6-16.6 -612.5%  
Current ratio x3.20.8 419.7%  
Inventory Days Days9484 111.7%  
Debtors Days Days7451 145.1%  
Net fixed assets Rs m1,79155,712 3.2%   
Share capital Rs m534155 345.7%   
"Free" reserves Rs m10,32420,968 49.2%   
Net worth Rs m10,85826,265 41.3%   
Long term debt Rs m4117,169 0.2%   
Total assets Rs m11,59188,606 13.1%  
Interest coverage x260.91.0 26,682.5%   
Debt to equity ratio x00.7 0.6%  
Sales to assets ratio x0.10.7 16.5%   
Return on assets %14.14.9 288.2%  
Return on equity %15.04.2 361.6%  
Return on capital %15.211.6 131.3%  
Exports to sales %1.537.8 4.1%   
Imports to sales %21.016.5 127.3%   
Exports (fob) Rs m1921,933 0.1%   
Imports (cif) Rs m2639,567 2.8%   
Fx inflow Rs m1922,004 0.1%   
Fx outflow Rs m26411,749 2.2%   
Net fx Rs m-24410,255 -2.4%   
CASH FLOW
From Operations Rs m2368,026 2.9%  
From Investments Rs m-224-1,744 12.8%  
From Financial Activity Rs m-27-4,447 0.6%  
Net Cashflow Rs m-151,834 -0.8%  

Share Holding

Indian Promoters % 64.0 45.6 140.4%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 0.2 8.7 2.3%  
FIIs % 9.7 21.2 45.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 21.1 123.7%  
Shareholders   54,701 23,815 229.7%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   ORCHID PHARMA LTD  WYETH LTD  ABBOTT INDIA  UNICHEM LAB  DR. REDDYS LAB  

Compare ALEMBIC LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Sep 18, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - PANACEA BIOTECH COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS